Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
about
Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial BioenergeticsBezafibrate administration improves behavioral deficits and tau pathology in P301S miceSimvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice.Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats.Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer.Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial.Antioxidants in Huntington's disease.Peroxisome proliferator-activated receptor-γ cofactors in neurodegeneration.Quinolinic acid: an endogenous neurotoxin with multiple targets.Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy.Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.
P2860
Q26795417-F7558482-A87D-43A8-AE54-09CC4524F1DDQ28273620-6BACB631-7CE4-41C1-8CEB-0D57B2F7134FQ33725859-7446DD9E-0D79-4F5C-82E6-8B87FB7A8FFBQ34634984-05B4F51E-8A5A-429D-AA8C-08D674E7645AQ34685755-27CB6493-129F-4900-B54B-CAA338529D9AQ35577677-BBEFAA66-6516-4FF6-A461-51B0B06E06ABQ36980014-D5E8BDBC-6FFC-45C4-BA11-5673659A605AQ37964359-3045268E-C8D7-469B-A5BB-3150EB2E30FDQ38058026-7403A1B2-2FC1-40F3-BCFD-0026E7697A0CQ38148752-F608DBFC-EA0A-453F-9657-50DF03725E66Q42710539-553E0D03-200D-4C34-84C6-1CB1C3DBD738Q45297835-5D4215C3-0FAF-42E9-8F6C-7FE93C275686Q45298602-A23648FB-14F0-4F48-87BD-8335F23A70AEQ52902863-A928EB0C-B943-4A9C-B554-44BF379C384CQ53645972-BAF85E36-B449-4C41-A1C4-9DF3B3A8D76F
P2860
Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Pioglitazone ameliorates behav ...... ilon) in Huntington's disease.
@en
Pioglitazone ameliorates behav ...... ilon) in Huntington's disease.
@nl
type
label
Pioglitazone ameliorates behav ...... ilon) in Huntington's disease.
@en
Pioglitazone ameliorates behav ...... ilon) in Huntington's disease.
@nl
prefLabel
Pioglitazone ameliorates behav ...... ilon) in Huntington's disease.
@en
Pioglitazone ameliorates behav ...... ilon) in Huntington's disease.
@nl
P2093
P1476
Pioglitazone ameliorates behav ...... ilon) in Huntington's disease.
@en
P2093
Anil Kumar
Harikesh Kalonia
Puneet Kumar
P304
P356
10.1016/J.PBB.2010.04.018
P407
P577
2010-05-05T00:00:00Z